Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, CFO and Treasurer | May 16, 2023 | May 18, 2023 |
| Mersana Therapeutics, Inc.MRSN · Entity 69982 | Chief Financial Officer | January 23, 2019 | January 25, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date May 16, 2023 · Filed May 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 446,483 |
Reported balance
After 2023-05-16 transaction · row 1
1 source rowRow 1 · 2023-05-16 · Sale · Disposed 63,567 · Balance 446,483 F1: This sale was made automatically by the Issuer pursuant to the Issuer's previously adopted "sell-to-cover" policy to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on June 8, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer pursuant to the Issuer's previously adopted "sell-to-cover" policy to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on June 8, 2022.
Mersana Therapeutics, Inc.
Report date January 23, 2019 · Filed January 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2029-01-23 | Direct | 100,000 |
Reported balance
After 2019-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-23 · Grant · Acquired 100,000 · Balance 100,000 F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2023 Filed May 18, 2023 22:19 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 63,567 | $1.07 | $67,889.56 |
DisclosureSEC source: 0001562180-23-004253 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,483 F1 · shares: This sale was made automatically by the Issuer pursuant to the Issuer's previously adopted "sell-to-cover" policy to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on June 8, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:00 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 810 | $0.88 | $710.78 |
DisclosureSEC source: 0001562180-23-002197 · primarydocument.xml · nonDerivative · entry 2 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,050 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:00 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,400 | $0.88 | $5,616.00 |
DisclosureSEC source: 0001562180-23-002197 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,860 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,539 | $0.81 | $6,130.71 |
DisclosureSEC source: 0001562180-23-002038 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,260 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 294,300 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001562180-23-000831 · primarydocument.xml · derivative · entry 2 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,300 Underlying: Common Stock · 294,300 shares Expires 2033-01-31 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 196,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000831 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,799 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 12:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001562180-22-005001 · primarydocument.xml · derivative · entry 2 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-06-08 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock ("the Stock Option") was granted by the Issuer pursuant to the 2014 Plan. The Stock Option will vest and become exercisable in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 12:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005001 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,599 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"). The RSUs will vest in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:09 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 803 | $2.17 | $1,743.07 |
DisclosureSEC source: 0001562180-22-002160 · primarydocument.xml · nonDerivative · entry 3 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,599 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:09 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 225,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001562180-22-002160 · primarydocument.xml · derivative · entry 4 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-02-28 F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:09 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002160 · primarydocument.xml · nonDerivative · entry 2 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,402 F2 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:09 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,400 | $2.15 | $15,945.52 |
DisclosureSEC source: 0001562180-22-002160 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,402 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001562180-21-006188 · primarydocument.xml · derivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-09-30 F1 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 00:34 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 790 | $3.40 | $2,686.00 |
DisclosureSEC source: 0001562180-21-002543 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,802 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:19 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 7,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002358 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,592 F1 · shares: As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020. Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001562180-21-001767 · primarydocument.xml · derivative · entry 2 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-02-26 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001767 · primarydocument.xml · nonDerivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 280,000 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0000899243-20-018268 · doc4.xml · derivative · entry 1 Spellman David A · CIK 0001733204 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:07 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001104659-19-003415 · a4.xml · derivative · entry 1 Spellman David A · CIK 0001733204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:49 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $13.97 | $0.00 |
DisclosureSEC source: 0001104659-18-017502 · a4.xml · derivative · entry 1 Spellman David A · CIK 0001733204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2021-03-12 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on the first anniversary of the grant date and in equal quarterly installments over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.